{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:09:56Z","timestamp":1790820596026,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170274, 82100410, 82270410"],"award-info":[{"award-number":["82170274, 82100410, 82270410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The utilization of donation after circulatory death (DCD) hearts can enlarge the donor pool. However, DCD hearts suffer from serious ischemia\/reperfusion injury (IRI). Recent studies found that the activation of NLRP3 inflammasome could play a significant role in organ IRI. Mcc950, which is a novel inhibitor of the NLRP3 inflammasome, can be applied to treat various kinds of cardiovascular diseases. Therefore, we hypothesized that the treatment of mcc950 could protect DCD hearts preserved with normothermic <jats:italic>ex vivo<\/jats:italic> heart perfusion (EVHP) against myocardial IRI <jats:italic>via<\/jats:italic> inhibiting NLRP3 inflammasome in a rat heart transplantation model of DCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Donor-heart rats were randomly divided into four groups: Control group; Vehicle group; MP-mcc950 group; and MP\u2009+\u2009PO-mcc950 group. Mcc950 was added into the perfusate of normothermic EVHP in the MP-mcc950 and MP\u2009+\u2009PO-mcc950 groups, and was injected into the left external jugular vein after heart transplantation in the MP\u2009+\u2009PO-mcc950 group. Cardiac functional assessment was performed. The level of oxidative stress, inflammatory response, apoptosis, and NLRP3 inflammasome-associated protein of donor hearts were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The treatment with mcc950 significantly increased the developed pressure (DP), dP\/dt<jats:sub>max<\/jats:sub>, and dP\/dt<jats:sub>min<\/jats:sub> of the left ventricular of DCD hearts at 90\u2005min after heart transplantation in both MP-mcc950 and MP\u2009+\u2009PO-mcc950 groups. Furthermore, mcc950 added into perfusate and injected after transplantation in both MP-mcc950 and MP\u2009+\u2009PO-mcc950 groups significantly attenuated the level of oxidative stress, inflammatory response, apoptosis, and NLRP3 inflammasome compared with the vehicle group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Normothermic EVHP combined with mcc950 treatment can be a promising and novel DCD heart preservation strategy, which can alleviate myocardial IRI <jats:italic>via<\/jats:italic> inhibiting NLRP3 inflammasome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1126391","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:51:31Z","timestamp":1679028691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation"],"prefix":"10.3389","volume":"10","author":[{"given":"Liwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"B1","first-page":"27","article-title":"An update on cardiac transplantation in the United States","author":"Everly","year":"2014","journal-title":"Clin Transpl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.117.029753","article-title":"Honoring 50 years of clinical heart transplantation in circulation: in-depth state-of-the-art review","volume":"137","author":"Stehlik","year":"2018","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1213\/ANE.0000000000003919","article-title":"New strategies to expand and optimize heart donor pool: ex vivo heart perfusion and donation after circulatory death: a review of current research and future trends","volume":"128","author":"Beuth","year":"2019","journal-title":"Anesth Analg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1089\/ars.2014.6125","article-title":"Hierarchical regulation of wound healing by NOD-like receptors in cardiovascular disease","volume":"22","author":"Bracey","year":"2015","journal-title":"Antioxid Redox Signaling"},{"key":"B5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2217\/fca.12.11","article-title":"Heart transplantation in adults with end-stage congenital heart disease","volume":"8","author":"Burchill","year":"2012","journal-title":"Future Cardiol"},{"key":"B6","first-page":"4264580","article-title":"Protective effect of ethyl pyruvate against myocardial ischemia reperfusion injury through regulations of ROS-related NLRP3 inflammasome activation","volume":"2019","author":"Jun","year":"2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10557-020-07104-8","article-title":"miR-330-5p inhibits NLRP3 inflammasome-mediated myocardial ischaemia-reperfusion injury by targeting TIM3","volume":"35","author":"Zuo","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jss.2020.08.020","article-title":"Modulation of interleukin-1 and -18 mediated injury in donation after circulatory death mouse hearts","volume":"257","author":"Quader","year":"2021","journal-title":"J Surg Res"},{"key":"B9","first-page":"5","article-title":"Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases","volume":"113","author":"Liu","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","article-title":"Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950","volume":"73","author":"Corcoran","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/TP.0000000000002461","article-title":"Effect of the selective NLRP3 inflammasome inhibitor mcc950 on transplantation outcome in a pig liver transplantation model with organs from donors after circulatory death preserved by hypothermic machine perfusion","volume":"103","author":"Yu","year":"2019","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.trim.2020.101293","article-title":"The NLRP3 inhibitor Mcc950 attenuates acute allograft damage in rat kidney transplants","volume":"61","author":"Zou","year":"2020","journal-title":"Transpl Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19305","DOI":"10.1038\/s41598-021-98437-3","article-title":"The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages","volume":"11","author":"Zeng","year":"2021","journal-title":"Sci Rep"},{"key":"B14","first-page":"2358","article-title":"(18)F-FDG PET imaging of myocardial inflammation and viability following experimental infarction and anti-inflammatory treatment with compound MCC950","volume":"28","author":"Jong","year":"2021"},{"key":"B15","doi-asserted-by":"crossref","first-page":"823387","DOI":"10.3389\/fcell.2022.823387","article-title":"NLRP3-Mediated Inflammation in atherosclerosis and associated therapeutics","volume":"10","author":"Lu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"733183","DOI":"10.3389\/fcell.2021.733183","article-title":"Normothermic ex vivo heart perfusion combined with melatonin enhances myocardial protection in rat donation after circulatory death hearts via inhibiting NLRP3 inflammasome-mediated pyroptosis","volume":"9","author":"Lu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ajt.12994","article-title":"Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors","volume":"15","author":"Iyer","year":"2015","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/toxsci\/50.2.271","article-title":"Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant sprague-dawley rats","volume":"50","author":"Jahnke","year":"1999","journal-title":"Toxicol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1080\/15548627.2020.1848971","article-title":"Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy","volume":"17","author":"Lin","year":"2021","journal-title":"Autophagy"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-020-02114-7","article-title":"Donor heart preservation with hypoxic-conditioned medium-derived from bone marrow mesenchymal stem cells improves cardiac function in a heart transplantation model","volume":"12","author":"Zhou","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/ajt.15843","article-title":"Brain-dead donor heart conservation with a preservation solution supplemented by a conditioned medium from mesenchymal stem cells improves graft contractility after transplantation","volume":"20","author":"Korkmaz-Ic\u00f6z","year":"2020","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/FJC.0000000000000709","article-title":"Cell-Specific roles of NLRP3 inflammasome in myocardial infarction","volume":"74","author":"Takahashi","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","first-page":"e934255","article-title":"Role of NLRP3 inflammasome in myocardial ischemia-reperfusion injury and ventricular remodeling","volume":"28","author":"Shen","year":"2022","journal-title":"Med Sci Monit"},{"key":"B25","first-page":"5271251","article-title":"Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia\/reperfusion injury by activation of RISK and mitochondrial pathways","volume":"2016","author":"Mastrocola","year":"2016"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-021-07282-z","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 mitigates post-resuscitation myocardial dysfunction and improves survival in a rat model of cardiac arrest and resuscitation","author":"Zheng","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"112133","DOI":"10.1016\/j.biopha.2021.112133","article-title":"MCC950 Attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis","volume":"143","author":"Zhang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00352","article-title":"Reactive oxygen species at the crossroads of inflammasome and inflammation","volume":"5","author":"Harijith","year":"2014","journal-title":"Front Physiol"},{"key":"B29","first-page":"26","article-title":"The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis)","volume":"297","author":"Zheng","year":"2020"},{"key":"B30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e762","DOI":"10.1002\/iid3.762","article-title":"Role of signal transduction pathways in IL-1\u03b2-induced apoptosis: pathological and therapeutic aspects","volume":"11","author":"Wang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"B32","doi-asserted-by":"crossref","first-page":"105350","DOI":"10.1016\/j.tiv.2022.105350","article-title":"Puerarin attenuates LPS-induced inflammatory injury in gastric epithelial cells by repressing NLRP3 inflammasome-mediated apoptosis","volume":"81","author":"Peng","year":"2022","journal-title":"Toxicol In Vitro"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1126391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:51:40Z","timestamp":1679028700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1126391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2023.1126391"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1126391","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"article-number":"1126391"}}